drTarget portfolio target-disease associations for cancer

OpenTargets offers > 140k target-disease associations from PChem targets suitable for virtual screening based in OpenTargets scores for all kind of tumours. See here the best scored pairs.

Target-disease associations for several types of cancer.

Check best scored target-disease associations in table:

PubChemAssay	program	assayType	testedComopunds	activeCompounds	diseaseName	weightedScore	weightedEvidence
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	targetBased	217959	2390	acute myeloid leukemia	0.694746124032017	594
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	targetBased	359207	1432	acute myeloid leukemia	0.529206458958698	625
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	targetBased	143816	859	acute myeloid leukemia	0.514639149025548	44
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	acute myeloid leukemia	0.820990723759405	3172
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	acute myeloid leukemia	0.820990723759405	3172
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	acute myeloid leukemia	0.820990723759405	3172
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	acute myeloid leukemia	0.820990723759405	3172
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	acute myeloid leukemia	0.820990723759405	3172
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2_inhibitors	targetBased	57013	201	acute myeloid leukemia	0.563380212187245	510
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	targetBased	359244	2975	acute myeloid leukemia	0.718076005186988	918
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	targetBased	215667	993	acute myeloid leukemia	0.830898626678178	3529
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	targetBased	218234	1620	acute myeloid leukemia	0.830898626678178	3529
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	Hodgkins lymphoma	0.651414538506129	246
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	targetBased	194628	267	acute myeloid leukemia	0.549734792816803	69
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	targetBased	359207	1432	T-cell acute lymphoblastic leukemia	0.518323037311425	58
Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3	HDAC3	targetBased	318291	483	unspecified peripheral T-cell lymphoma	0.566224706091656	20
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	unspecified peripheral T-cell lymphoma	0.624986273516276	69
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	targetBased	217959	2390	acute lymphoblastic leukemia	0.671778593539966	457
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	targetBased	359207	1432	acute lymphoblastic leukemia	0.821223780852646	2618
qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS	TXNRD1	targetBased	386663	3977	acute promyelocytic leukemia	0.622116387379182	33
Development of Small Molecule Probes of the Histone Methyltransferase, NSD2 Measured in Biochemical System Using Plate Reader - 7053-01_Inhibitor_SinglePoint_HTS_Activity_Set2	NSD2	targetBased	309684	1662	acute lymphoblastic leukemia	0.503855438557983	70
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	targetBased	143816	859	myelodysplastic syndrome	0.603738282918877	75
qHTS for Inhibitors of TGF-b	TGFB1	pathwayBased	403345	4970	myelodysplastic syndrome	0.629372173160002	108
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	targetBased	359244	2975	myelodysplastic syndrome	0.677763361237735	571
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	acute lymphoblastic leukemia	0.655097189866326	1529
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	acute lymphoblastic leukemia	0.655097189866326	1529
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	acute lymphoblastic leukemia	0.655097189866326	1529
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	acute lymphoblastic leukemia	0.655097189866326	1529
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	acute lymphoblastic leukemia	0.655097189866326	1529
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	myelodysplastic syndrome	0.533745835566975	780
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	myelodysplastic syndrome	0.533745835566975	780
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	myelodysplastic syndrome	0.533745835566975	780
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	myelodysplastic syndrome	0.533745835566975	780
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	myelodysplastic syndrome	0.533745835566975	780
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	targetBased	215667	993	acute lymphoblastic leukemia	0.551609117000469	1706
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	targetBased	218234	1620	acute lymphoblastic leukemia	0.551609117000469	1706
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	chronic lymphocytic leukemia	0.791053421387467	1441
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	chronic lymphocytic leukemia	0.791053421387467	1441
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	chronic lymphocytic leukemia	0.791053421387467	1441
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	chronic lymphocytic leukemia	0.791053421387467	1441
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	chronic lymphocytic leukemia	0.791053421387467	1441
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	chronic lymphocytic leukemia	0.721306850470058	362
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	acute lymphoblastic leukemia	0.655164699314168	219
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	adenocarcinoma	0.557676411022396	7865
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	adenocarcinoma	0.557676411022396	7865
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	adenocarcinoma	0.557676411022396	7865
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	adenocarcinoma	0.557676411022396	7865
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	adenocarcinoma	0.557676411022396	7865
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	adenocarcinoma	0.718867795822544	302
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	gastric carcinoma	0.544948834234569	37
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	gastric carcinoma	0.557967975359973	759
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	gastric carcinoma	0.557967975359973	759
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	gastric carcinoma	0.557967975359973	759
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	gastric carcinoma	0.557967975359973	759
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	gastric carcinoma	0.557967975359973	759
qHTS for Inhibitors of WRN Helicase	WRN	targetBased	364011	1678	gastric carcinoma	0.524091359604701	8
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	breast adenocarcinoma	0.835161405915504	527
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	breast adenocarcinoma	0.835161405915504	527
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	breast adenocarcinoma	0.835161405915504	527
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	breast adenocarcinoma	0.835161405915504	527
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	breast adenocarcinoma	0.835161405915504	527
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	targetBased	356517	1139	breast adenocarcinoma	0.76578869022397	161
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	targetBased	194628	267	bladder tumor	0.55177181402749	130
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	adenocarcinoma	0.590697931637223	315
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	pathwayBased	376029	3978	breast adenocarcinoma	0.536209548600684	198
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	targetBased	86095	1442	breast adenocarcinoma	0.696683621141791	918
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	targetBased	86095	1151	breast adenocarcinoma	0.696683621141791	918
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	Ewing sarcoma	0.586304863474545	249
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	Ewing sarcoma	0.586304863474545	249
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	Ewing sarcoma	0.586304863474545	249
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	Ewing sarcoma	0.586304863474545	249
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	Ewing sarcoma	0.586304863474545	249
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2_inhibitors	targetBased	57013	201	neoplasm of mature B-cells	0.553583014844976	351
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	breast adenocarcinoma	0.508319648934431	47
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	targetBased	359518	300	adenoma	0.529784692452108	89
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	targetBased	335652	1779	adenoma	0.529784692452108	89
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	targetBased	362274	1056	adenoma	0.529784692452108	89
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	targetBased	336308	6862	adenoma	0.529784692452108	89
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	targetBased	357537	806	adenoma	0.529784692452108	89
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	targetBased	339887	1178	adenoma	0.529784692452108	89
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	targetBased	334825	423	colorectal adenocarcinoma	0.564864589281233	18
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	targetBased	337446	1356	colorectal adenocarcinoma	0.564864589281233	18
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	adenoid cystic carcinoma	0.513954747920079	22
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	adenoid cystic carcinoma	0.513954747920079	22
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	adenoid cystic carcinoma	0.513954747920079	22
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	adenoid cystic carcinoma	0.513954747920079	22
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	adenoid cystic carcinoma	0.513954747920079	22
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	colorectal adenocarcinoma	0.746609442237671	429
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	colorectal adenocarcinoma	0.746609442237671	429
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	colorectal adenocarcinoma	0.746609442237671	429
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	colorectal adenocarcinoma	0.746609442237671	429
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	colorectal adenocarcinoma	0.746609442237671	429
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	pathwayBased	376029	3978	breast carcinoma	0.938370121037582	9141
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	targetBased	86095	1442	breast carcinoma	0.852709036989038	5420
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	targetBased	86095	1151	breast carcinoma	0.852709036989038	5420
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	targetBased	334825	423	head and neck squamous cell carcinoma	0.511667802800374	19
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	targetBased	337446	1356	head and neck squamous cell carcinoma	0.511667802800374	19
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay	MAPK1	pathwayBased	70898	707	head and neck squamous cell carcinoma	0.553293708152968	66
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF	MAPK1	pathwayBased	131324	544	head and neck squamous cell carcinoma	0.553293708152968	66
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2_inhibitors	targetBased	57013	201	breast carcinoma	0.530249603412033	201
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	adrenal gland pheochromocytoma	0.539378622906823	39
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	adrenal gland pheochromocytoma	0.539378622906823	39
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	adrenal gland pheochromocytoma	0.539378622906823	39
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	adrenal gland pheochromocytoma	0.539378622906823	39
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	adrenal gland pheochromocytoma	0.539378622906823	39
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	targetBased	356517	1139	colorectal adenocarcinoma	0.67820446347352	59
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	colorectal adenocarcinoma	0.672688746591176	19
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	head and neck squamous cell carcinoma	0.500992087079442	21
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	head and neck squamous cell carcinoma	0.500992087079442	21
qHTS for Inhibitors of WRN Helicase	WRN	targetBased	364011	1678	colorectal adenocarcinoma	0.550149135016612	6
Nrf2 qHTS screen for inhibitors	nrf2Inhibitors	targetBased	360873	7438	head and neck squamous cell carcinoma	0.638949556374262	113
qHTS of Nrf2 Activators	Nrf2 activators	pathwayBased	403871	1243	head and neck squamous cell carcinoma	0.638949556374262	113
HTS of Smad transcription factor inhibitors	SMAD3	targetBased	88033	251	colorectal adenocarcinoma	0.658346544341343	17
uHTS identification of Caspase-8 TRAIL sensitizers in a luminesence assay	TNFRSF10B	targetBased	363840	3764	head and neck squamous cell carcinoma	0.517986428422721	40
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	targetBased	86095	1114	breast carcinoma	0.639892659510695	224
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	breast carcinoma	0.742846429132578	2349
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	breast carcinoma	0.742846429132578	2349
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	breast carcinoma	0.742846429132578	2349
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	breast carcinoma	0.742846429132578	2349
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	breast carcinoma	0.742846429132578	2349
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	targetBased	356517	1139	breast carcinoma	0.79025743556127	934
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	pathwayBased	43989	342	colorectal adenocarcinoma	0.516313607375484	40
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	breast carcinoma	0.73759684515586	1997
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac activated mutant	RAC1	targetBased	194629	219	head and neck squamous cell carcinoma	0.559322758217218	35
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac wildtype	RAC1	targetBased	194628	521	head and neck squamous cell carcinoma	0.559322758217218	35
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	head and neck squamous cell carcinoma	0.872621428237112	3127
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	head and neck squamous cell carcinoma	0.872621428237112	3127
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	head and neck squamous cell carcinoma	0.872621428237112	3127
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	head and neck squamous cell carcinoma	0.872621428237112	3127
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	head and neck squamous cell carcinoma	0.872621428237112	3127
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	targetBased	193542	587	head and neck squamous cell carcinoma	0.531641034089883	101
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	targetBased	194628	267	head and neck squamous cell carcinoma	0.708595202152874	261
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	breast carcinoma	0.682065381231255	257
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	head and neck squamous cell carcinoma	0.608750307574734	185
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	astrocytoma	0.573950587211972	792
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	astrocytoma	0.573950587211972	792
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	astrocytoma	0.573950587211972	792
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	astrocytoma	0.573950587211972	792
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	astrocytoma	0.573950587211972	792
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	chromophobe renal cell carcinoma	0.597239078637754	77
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	chromophobe renal cell carcinoma	0.597239078637754	77
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	chromophobe renal cell carcinoma	0.597239078637754	77
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	chromophobe renal cell carcinoma	0.597239078637754	77
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	chromophobe renal cell carcinoma	0.597239078637754	77
Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity	SMARCA4	targetBased	344733	7043	Burkitts lymphoma	0.583982765294942	29
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	Burkitts lymphoma	0.58936406559799	275
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	Burkitts lymphoma	0.58936406559799	275
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	Burkitts lymphoma	0.58936406559799	275
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	Burkitts lymphoma	0.58936406559799	275
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	Burkitts lymphoma	0.58936406559799	275
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	targetBased	217959	2390	chronic myelogenous leukemia	0.509598213983665	271
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	targetBased	359207	1432	chronic myelogenous leukemia	0.920783141818354	6490
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	pathwayBased	376029	3978	carcinoma	0.550324090196856	10180
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	targetBased	334825	423	cutaneous melanoma	0.566105204863099	9
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	targetBased	337446	1356	cutaneous melanoma	0.566105204863099	9
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2_inhibitors	targetBased	57013	201	cutaneous melanoma	0.521864485975192	44
Nrf2 qHTS screen for inhibitors	nrf2Inhibitors	targetBased	360873	7438	hepatocellular carcinoma	0.717676555746485	407
qHTS of Nrf2 Activators	Nrf2 activators	pathwayBased	403871	1243	hepatocellular carcinoma	0.717676555746485	407
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac activated mutant	RAC1	targetBased	194629	219	cutaneous melanoma	0.60668394398872	21
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac wildtype	RAC1	targetBased	194628	521	cutaneous melanoma	0.60668394398872	21
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	cutaneous melanoma	0.600703099701458	325
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	cutaneous melanoma	0.600703099701458	325
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	cutaneous melanoma	0.600703099701458	325
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	cutaneous melanoma	0.600703099701458	325
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	cutaneous melanoma	0.600703099701458	325
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	targetBased	86095	1114	carcinoma	0.608626082644483	601
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	carcinoma	0.624221075469731	20998
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	carcinoma	0.624221075469731	20998
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	carcinoma	0.624221075469731	20998
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	carcinoma	0.624221075469731	20998
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	carcinoma	0.624221075469731	20998
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	targetBased	108286	1415	carcinoma	0.551307642137785	39
HTS for BAP1 Enzyme inhibitors	BAP1_inhibitors	targetBased	71016	346	cutaneous melanoma	0.50942246785541	78
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	targetBased	193542	587	cutaneous melanoma	0.566976009544841	60
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	targetBased	194628	267	cutaneous melanoma	0.573097734825806	104
MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity	MITF	targetBased	331360	2760	cutaneous melanoma	0.783010945534478	722
AlphaScreen-based biochemical high throughput primary assay to identify inhibitors of microphthalmia-associated transcription factor (MITF)	MITF inhibitors	targetBased	642362	5830	cutaneous melanoma	0.783010945534478	722
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	pathwayBased	43989	342	cutaneous melanoma	0.567767359841182	34
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	targetBased	86095	1114	hepatocellular carcinoma	0.570526943027433	87
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	hepatocellular carcinoma	0.891165571922842	7068
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	hepatocellular carcinoma	0.891165571922842	7068
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	hepatocellular carcinoma	0.891165571922842	7068
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	hepatocellular carcinoma	0.891165571922842	7068
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	hepatocellular carcinoma	0.891165571922842	7068
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	carcinoma	0.620413702006112	1700
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	targetBased	193542	587	hepatocellular carcinoma	0.875521957433293	1848
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	targetBased	194628	267	hepatocellular carcinoma	0.528549083483217	245
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2_inhibitors	targetBased	57013	201	diffuse large B-cell lymphoma	0.677996101121258	565
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	targetBased	217959	2390	essential thrombocythemia	0.753090144400383	1853
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	targetBased	359244	2975	diffuse large B-cell lymphoma	0.531063254206481	67
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	clear cell renal carcinoma	0.510792843766613	21
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	clear cell renal carcinoma	0.510792843766613	21
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	clear cell renal carcinoma	0.510792843766613	21
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	clear cell renal carcinoma	0.510792843766613	21
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	clear cell renal carcinoma	0.510792843766613	21
HTS for BAP1 Enzyme inhibitors	BAP1_inhibitors	targetBased	71016	346	clear cell renal carcinoma	0.687745221766357	15
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	diffuse large B-cell lymphoma	0.743259744045603	845
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	diffuse large B-cell lymphoma	0.743259744045603	845
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	diffuse large B-cell lymphoma	0.743259744045603	845
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	diffuse large B-cell lymphoma	0.743259744045603	845
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	diffuse large B-cell lymphoma	0.743259744045603	845
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	pathwayBased	194666	1772	diffuse large B-cell lymphoma	0.592602942376381	397
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	pathwayBased	194666	1722	diffuse large B-cell lymphoma	0.592602942376381	397
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	pathwayBased	43989	342	clear cell renal carcinoma	0.620163172618119	38
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	diffuse large B-cell lymphoma	0.651733669028007	342
Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	targetBased	329153	670	follicular thyroid adenoma	0.540640624407186	22
Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	targetBased	329153	670	follicular thyroid adenoma	0.540640624407186	22
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor	TSHR	targetBased	72026	352	follicular thyroid adenoma	0.540640624407186	22
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293	TSHR	targetBased	72026	1794	follicular thyroid adenoma	0.540640624407186	22
HTS for BAP1 Enzyme inhibitors	BAP1_inhibitors	targetBased	71016	346	hepatocellular carcinoma	0.581453884185817	29
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	targetBased	194628	267	follicular thyroid carcinoma	0.755392732456168	65
Dicer-mediated maturation of pre-microRNA	Dicer_inhibitors	targetBased	46715	2829	embryonal rhabdomyosarcoma	0.769159310314872	123
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	gastric adenocarcinoma	0.798791596621054	633
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	gastric adenocarcinoma	0.798791596621054	633
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	gastric adenocarcinoma	0.798791596621054	633
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	gastric adenocarcinoma	0.798791596621054	633
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	gastric adenocarcinoma	0.798791596621054	633
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	targetBased	193542	587	gastric adenocarcinoma	0.575548071830238	88
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	targetBased	194628	267	gastric adenocarcinoma	0.533364555936172	31
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	leiomyosarcoma	0.579427927799183	247
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	leiomyosarcoma	0.579427927799183	247
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	leiomyosarcoma	0.579427927799183	247
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	leiomyosarcoma	0.579427927799183	247
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	leiomyosarcoma	0.579427927799183	247
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	targetBased	359207	1432	leukemia	0.718194542732695	3745
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	leukemia	0.500371196337833	17
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	leukemia	0.500371196337833	17
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	targetBased	359244	2975	leukemia	0.518197290267351	503
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	papillary renal cell carcinoma	0.567761442812016	128
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	papillary renal cell carcinoma	0.567761442812016	128
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	papillary renal cell carcinoma	0.567761442812016	128
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	papillary renal cell carcinoma	0.567761442812016	128
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	papillary renal cell carcinoma	0.567761442812016	128
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	pathwayBased	194666	1772	leukemia	0.585207833502101	486
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	pathwayBased	194666	1722	leukemia	0.585207833502101	486
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	leukemia	0.52960653881427	339
qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM)	BLM_inhibitors	targetBased	347933	673	leukemia	0.572630433777704	14
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	pathwayBased	43989	342	papillary renal cell carcinoma	0.571926902752998	24
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	targetBased	336894	489	lung adenocarcinoma	0.68606434581265	211
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	neuroblastoma	0.507751259134717	1059
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	neuroblastoma	0.507751259134717	1059
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	neuroblastoma	0.507751259134717	1059
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	neuroblastoma	0.507751259134717	1059
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	neuroblastoma	0.507751259134717	1059
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	glioblastoma multiforme	0.709913256686522	2001
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	glioblastoma multiforme	0.709913256686522	2001
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	glioblastoma multiforme	0.709913256686522	2001
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	glioblastoma multiforme	0.709913256686522	2001
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	glioblastoma multiforme	0.709913256686522	2001
Nrf2 qHTS screen for inhibitors	nrf2Inhibitors	targetBased	360873	7438	lung adenocarcinoma	0.515767117951293	97
qHTS of Nrf2 Activators	Nrf2 activators	pathwayBased	403871	1243	lung adenocarcinoma	0.515767117951293	97
Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity	SMARCA4	targetBased	344733	7043	lung adenocarcinoma	0.636562053600706	51
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	targetBased	194628	267	nevus	0.571671843940988	81
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	lung adenocarcinoma	0.834485116926117	1395
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	lung adenocarcinoma	0.834485116926117	1395
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	lung adenocarcinoma	0.834485116926117	1395
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	lung adenocarcinoma	0.834485116926117	1395
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	lung adenocarcinoma	0.834485116926117	1395
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	lung adenocarcinoma	0.62431172792332	91
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	targetBased	193542	587	lung adenocarcinoma	0.61641044122721	104
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	targetBased	194628	267	lung adenocarcinoma	0.565482845742141	126
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	osteosarcoma	0.793475959159254	405
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	osteosarcoma	0.793475959159254	405
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	osteosarcoma	0.793475959159254	405
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	osteosarcoma	0.793475959159254	405
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	osteosarcoma	0.793475959159254	405
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	targetBased	143816	859	lymphoma	0.578691902621926	614
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2_inhibitors	targetBased	57013	201	lymphoma	0.661365156411374	554
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	lymphoma	0.692516703724469	2300
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	lymphoma	0.692516703724469	2300
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	lymphoma	0.692516703724469	2300
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	lymphoma	0.692516703724469	2300
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	lymphoma	0.692516703724469	2300
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	pathwayBased	194666	1772	lymphoma	0.51373824732454	888
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	pathwayBased	194666	1722	lymphoma	0.51373824732454	888
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	lymphoma	0.654474277762646	1237
qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM)	BLM_inhibitors	targetBased	347933	673	lymphoma	0.566768728375716	18
HTS for BAP1 Enzyme inhibitors	BAP1_inhibitors	targetBased	71016	346	mesothelioma	0.605356658796186	276
uHTS identification of HIF-2a Inhibitors in a luminesence assay	HIF-2a_inhibitors	targetBased	363840	2624	renal cell carcinoma	0.707437226974782	676
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	renal cell carcinoma	0.633336943115504	1152
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	renal cell carcinoma	0.633336943115504	1152
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	renal cell carcinoma	0.633336943115504	1152
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	renal cell carcinoma	0.633336943115504	1152
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	renal cell carcinoma	0.633336943115504	1152
HTS for BAP1 Enzyme inhibitors	BAP1_inhibitors	targetBased	71016	346	renal cell carcinoma	0.581080744195547	138
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	pathwayBased	43989	342	renal cell carcinoma	0.593783534704895	1898
Dicer-mediated maturation of pre-microRNA	Dicer_inhibitors	targetBased	46715	2829	melanoma	0.532731295041119	55
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2_inhibitors	targetBased	57013	201	melanoma	0.536984685004855	430
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac activated mutant	RAC1	targetBased	194629	219	melanoma	0.70849417048193	39
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac wildtype	RAC1	targetBased	194628	521	melanoma	0.70849417048193	39
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	prostate adenocarcinoma	0.804334708461005	352
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	prostate adenocarcinoma	0.804334708461005	352
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	prostate adenocarcinoma	0.804334708461005	352
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	prostate adenocarcinoma	0.804334708461005	352
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	prostate adenocarcinoma	0.804334708461005	352
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	targetBased	356517	1139	prostate adenocarcinoma	0.613766243992196	71
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	prostate adenocarcinoma	0.71034534298668	56
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	melanoma	0.727160629242358	2492
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	melanoma	0.727160629242358	2492
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	melanoma	0.727160629242358	2492
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	melanoma	0.727160629242358	2492
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	melanoma	0.727160629242358	2492
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	targetBased	356517	1139	melanoma	0.500221889593926	2582
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	pathwayBased	376029	3978	neoplasm	0.838869652727156	24991
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	targetBased	193542	587	prostate adenocarcinoma	0.731249965361392	63
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	targetBased	194628	267	prostate adenocarcinoma	0.543234231990126	23
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2_inhibitors	targetBased	57013	201	sarcoma	0.57334986414968	191
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	targetBased	334825	423	neoplasm	0.624327417617625	1348
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	targetBased	337446	1356	neoplasm	0.624327417617625	1348
HTS for BAP1 Enzyme inhibitors	BAP1_inhibitors	targetBased	71016	346	melanoma	0.555227813487309	130
qHTS for Inhibitors of WRN Helicase	WRN	targetBased	364011	1678	melanoma	0.54225293911469	19
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	targetBased	193542	587	melanoma	0.707371985908243	295
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	sarcoma	0.714640176905728	2314
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	sarcoma	0.714640176905728	2314
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	sarcoma	0.714640176905728	2314
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	sarcoma	0.714640176905728	2314
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	sarcoma	0.714640176905728	2314
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	prostate adenocarcinoma	0.609422103028697	210
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	sarcoma	0.510898490357025	221
MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity	MITF	targetBased	331360	2760	melanoma	0.53648241518688	2725
AlphaScreen-based biochemical high throughput primary assay to identify inhibitors of microphthalmia-associated transcription factor (MITF)	MITF inhibitors	targetBased	642362	5830	melanoma	0.53648241518688	2725
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	targetBased	86095	1442	neoplasm	0.797175874096195	36242
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	targetBased	86095	1151	neoplasm	0.797175874096195	36242
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	targetBased	217959	2390	neoplasm	0.832471458207819	8077
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	targetBased	359207	1432	neoplasm	0.773198977841017	6645
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	targetBased	143816	859	neoplasm	0.546980995818396	895
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2_inhibitors	targetBased	57013	201	neoplasm	0.649002328313517	9186
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	neoplasm	0.668792435509745	475
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	neoplasm	0.668792435509745	475
uHTS identification of HIF-2a Inhibitors in a luminesence assay	HIF-2a_inhibitors	targetBased	363840	2624	neoplasm	0.634731505143747	3280
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	targetBased	336894	489	squamous cell lung carcinoma	0.591749999583246	57
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	335	neoplasm	0.519243461811769	4416
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	782	neoplasm	0.519243461811769	4416
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	390	neoplasm	0.519243461811769	4416
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	811	neoplasm	0.519243461811769	4416
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	670	neoplasm	0.519243461811769	4416
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	519	neoplasm	0.519243461811769	4416
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	targetBased	359244	2975	neoplasm	0.657839573780106	4779
qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide	Menin-MLL_inhibitors	targetBased	263421	615	neoplasm	0.510157872963492	4780
Nrf2 qHTS screen for inhibitors	nrf2Inhibitors	targetBased	360873	7438	squamous cell lung carcinoma	0.700426818850629	89
qHTS of Nrf2 Activators	Nrf2 activators	pathwayBased	403871	1243	squamous cell lung carcinoma	0.700426818850629	89
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	small cell lung carcinoma	0.743850543799876	1614
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	small cell lung carcinoma	0.743850543799876	1614
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	small cell lung carcinoma	0.743850543799876	1614
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	small cell lung carcinoma	0.743850543799876	1614
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	small cell lung carcinoma	0.743850543799876	1614
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	squamous cell lung carcinoma	0.782904796477414	523
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	squamous cell lung carcinoma	0.782904796477414	523
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	squamous cell lung carcinoma	0.782904796477414	523
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	squamous cell lung carcinoma	0.782904796477414	523
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	squamous cell lung carcinoma	0.782904796477414	523
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	targetBased	194628	267	squamous cell lung carcinoma	0.577906415694614	34
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	squamous cell lung carcinoma	0.585836319535447	61
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	targetBased	86095	1114	neoplasm	0.66776754745673	3322
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	neoplasm	0.734763617551086	117109
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	neoplasm	0.734763617551086	117109
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	neoplasm	0.734763617551086	117109
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	neoplasm	0.734763617551086	117109
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	neoplasm	0.734763617551086	117109
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	targetBased	356517	1139	neoplasm	0.563185687279908	52761
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	targetBased	359518	300	neoplasm	0.505795193234879	607
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	targetBased	335652	1779	neoplasm	0.505795193234879	607
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	targetBased	362274	1056	neoplasm	0.505795193234879	607
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	targetBased	336308	6862	neoplasm	0.505795193234879	607
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	targetBased	357537	806	neoplasm	0.505795193234879	607
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	targetBased	339887	1178	neoplasm	0.505795193234879	607
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	neoplasm	0.87594830406283	8058
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	squamous cell carcinoma	0.691147782991076	5273
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	squamous cell carcinoma	0.691147782991076	5273
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	squamous cell carcinoma	0.691147782991076	5273
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	squamous cell carcinoma	0.691147782991076	5273
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	squamous cell carcinoma	0.691147782991076	5273
uHTS luminescence assay for the identification of compounds that inhibit NOD2	NOD2	targetBased	292323	1836	neoplasm	0.582604832960078	313
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	targetBased	193542	587	neoplasm	0.655184857451428	8177
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	targetBased	305610	3794	neoplasm	0.591556848961583	113
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	targetBased	194628	267	squamous cell carcinoma	0.561703048438636	329
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	targetBased	339674	2841	neoplasm	0.583703277674933	62
Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3	HDAC3	targetBased	318291	483	neoplasm	0.669681742135009	1140
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	targetBased	194628	267	neoplasm	0.645516132179648	4509
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	squamous cell carcinoma	0.624144915124246	254
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	neoplasm	0.685425205092243	6252
qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS	TXNRD1	targetBased	386663	3977	neoplasm	0.546990287972955	620
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	pathwayBased	43989	342	neoplasm	0.541889017137273	28013
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	pathwayBased	376029	3978	ovarian carcinoma	0.811014153936412	630
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	targetBased	359207	1432	multiple myeloma	0.526059241881704	50
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	targetBased	143816	859	multiple myeloma	0.676525185755556	1089
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	ovarian carcinoma	0.564167801515414	1002
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	ovarian carcinoma	0.564167801515414	1002
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	ovarian carcinoma	0.564167801515414	1002
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	ovarian carcinoma	0.564167801515414	1002
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	ovarian carcinoma	0.564167801515414	1002
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	targetBased	356517	1139	ovarian carcinoma	0.661454282948221	250
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	multiple myeloma	0.739052515476112	726
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	multiple myeloma	0.739052515476112	726
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	multiple myeloma	0.739052515476112	726
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	multiple myeloma	0.739052515476112	726
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	multiple myeloma	0.739052515476112	726
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	targetBased	193542	587	ovarian carcinoma	0.528561751035599	76
Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3	HDAC3	targetBased	318291	483	multiple myeloma	0.62323885367771	117
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	targetBased	194628	267	multiple myeloma	0.524918664126389	29
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	multiple myeloma	0.624291315565239	141
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	anaplastic astrocytoma	0.569608536065496	177
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	anaplastic astrocytoma	0.569608536065496	177
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	anaplastic astrocytoma	0.569608536065496	177
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	anaplastic astrocytoma	0.569608536065496	177
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	anaplastic astrocytoma	0.569608536065496	177
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	cervical adenocarcinoma	0.538818108466208	100
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	cervical adenocarcinoma	0.538818108466208	100
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	cervical adenocarcinoma	0.538818108466208	100
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	cervical adenocarcinoma	0.538818108466208	100
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	cervical adenocarcinoma	0.538818108466208	100
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	targetBased	193542	587	cervical adenocarcinoma	0.520077721092215	24
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	targetBased	194628	267	cervical adenocarcinoma	0.522134222563113	17
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	targetBased	324747	813	cirrhosis of liver	0.543359118242622	6
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	targetBased	339297	1446	cirrhosis of liver	0.505376346678683	6
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	targetBased	359207	1432	lymphoid neoplasm	0.681165036449891	1079
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2_inhibitors	targetBased	57013	201	lymphoid neoplasm	0.635028303815862	555
Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity	SMARCA4	targetBased	344733	7043	lymphoid neoplasm	0.515089787821532	44
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	lymphoid neoplasm	0.673172901271881	2270
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	lymphoid neoplasm	0.673172901271881	2270
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	lymphoid neoplasm	0.673172901271881	2270
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	lymphoid neoplasm	0.673172901271881	2270
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	lymphoid neoplasm	0.673172901271881	2270
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	pathwayBased	194666	1772	lymphoid neoplasm	0.616157212101945	884
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	pathwayBased	194666	1722	lymphoid neoplasm	0.616157212101945	884
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	lymphoid neoplasm	0.56726113328905	802
qHTS for Inhibitors of Polymerase Kappa	POLK	targetBased	395295	2034	prostate carcinoma	0.599073001448264	42
Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3	HDAC3	targetBased	318291	483	Cutaneous T-cell lymphoma	0.562111104478172	44
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	prostate carcinoma	0.598179746256734	442
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	prostate carcinoma	0.598179746256734	442
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	prostate carcinoma	0.598179746256734	442
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	prostate carcinoma	0.598179746256734	442
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	prostate carcinoma	0.598179746256734	442
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	targetBased	356517	1139	prostate carcinoma	0.509965207659139	140
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	prostate carcinoma	0.648714094744205	50
Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.	BCL2L11_inhibitors	targetBased	325630	216	prostate carcinoma	0.515874114696088	13
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	esophageal carcinoma	0.631553488700546	1025
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	esophageal carcinoma	0.631553488700546	1025
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	esophageal carcinoma	0.631553488700546	1025
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	esophageal carcinoma	0.631553488700546	1025
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	esophageal carcinoma	0.631553488700546	1025
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	targetBased	193542	587	esophageal carcinoma	0.531275226876165	65
Dicer-mediated maturation of pre-microRNA	Dicer_inhibitors	targetBased	46715	2829	rhabdomyosarcoma	0.569574565978751	92
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	rhabdomyosarcoma	0.688273946449154	275
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	rhabdomyosarcoma	0.688273946449154	275
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	rhabdomyosarcoma	0.688273946449154	275
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	rhabdomyosarcoma	0.688273946449154	275
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	rhabdomyosarcoma	0.688273946449154	275
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	targetBased	336894	489	lung carcinoma	0.533631681825241	335
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	targetBased	217959	2390	myeloid neoplasm	0.545293990265582	4706
Nrf2 qHTS screen for inhibitors	nrf2Inhibitors	targetBased	360873	7438	lung carcinoma	0.536803382389076	198
qHTS of Nrf2 Activators	Nrf2 activators	pathwayBased	403871	1243	lung carcinoma	0.536803382389076	198
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2_inhibitors	targetBased	57013	201	myeloid neoplasm	0.539402074530581	535
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	targetBased	215667	993	myeloid neoplasm	0.552307095351119	1680
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	targetBased	218234	1620	myeloid neoplasm	0.552307095351119	1680
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	targetBased	217959	2390	chronic myeloproliferative disorder	0.509912994147925	5588
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	lung carcinoma	0.51063680830263	3214
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	lung carcinoma	0.51063680830263	3214
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	lung carcinoma	0.51063680830263	3214
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	lung carcinoma	0.51063680830263	3214
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	lung carcinoma	0.51063680830263	3214
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	targetBased	194628	267	rhabdomyosarcoma	0.566060561247714	32
Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity	SMARCA4	targetBased	344733	7043	medulloblastoma	0.636851805368641	16
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	medulloblastoma	0.623581877783622	55
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	medulloblastoma	0.623581877783622	55
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	medulloblastoma	0.623581877783622	55
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	medulloblastoma	0.623581877783622	55
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	medulloblastoma	0.623581877783622	55
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	targetBased	217959	2390	polycythemia vera	0.838231550055395	1434
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	targetBased	217959	2390	primary myelofibrosis	0.828570613464231	590
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	targetBased	193542	587	medulloblastoma	0.814044525642904	108
Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex	PRKAR1A	targetBased	343468	285	endocrine neoplasm	0.658688749369898	83
qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide	Menin-MLL_inhibitors	targetBased	263421	615	endocrine neoplasm	0.814230692322863	2441
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	endocrine neoplasm	0.629328151945855	4684
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	endocrine neoplasm	0.629328151945855	4684
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	endocrine neoplasm	0.629328151945855	4684
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	endocrine neoplasm	0.629328151945855	4684
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	endocrine neoplasm	0.629328151945855	4684
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	pathwayBased	376029	3978	pancreatic carcinoma	0.717108809180929	280
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	anaplastic large cell lymphoma	0.503028356338076	26
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	pancreatic carcinoma	0.772563433295667	611
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	pancreatic carcinoma	0.772563433295667	611
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	pancreatic carcinoma	0.772563433295667	611
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	pancreatic carcinoma	0.772563433295667	611
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	pancreatic carcinoma	0.772563433295667	611
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	pancreatic carcinoma	0.718784932807895	97
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	pathwayBased	376029	3978	breast neoplasm	0.969800044375086	10492
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	targetBased	86095	1442	breast neoplasm	0.835522351213338	6847
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	targetBased	86095	1151	breast neoplasm	0.835522351213338	6847
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	targetBased	86095	1114	breast neoplasm	0.630680665640952	453
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	breast neoplasm	0.755353716652497	2799
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	breast neoplasm	0.755353716652497	2799
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	breast neoplasm	0.755353716652497	2799
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	breast neoplasm	0.755353716652497	2799
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	breast neoplasm	0.755353716652497	2799
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	targetBased	356517	1139	breast neoplasm	0.66299167834792	1506
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	breast neoplasm	0.757177438416621	2227
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	targetBased	305610	3794	breast neoplasm	0.54706759205653	11
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	targetBased	339674	2841	breast neoplasm	0.544285598520276	6
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	targetBased	194628	267	breast neoplasm	0.536580295784799	144
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	breast neoplasm	0.678524544348591	1359
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	pathwayBased	43989	342	breast neoplasm	0.517897767902	729
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	pancreatic carcinoma	0.586465101589641	371
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	targetBased	336894	489	non-small cell lung carcinoma	0.655334675854879	718
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	targetBased	359244	2975	refractory anemia with excess blasts	0.634927526187759	20
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	renal carcinoma	0.521275564851696	754
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	renal carcinoma	0.521275564851696	754
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	renal carcinoma	0.521275564851696	754
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	renal carcinoma	0.521275564851696	754
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	renal carcinoma	0.521275564851696	754
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	pathwayBased	43989	342	renal carcinoma	0.590771525813295	872
Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity	SMARCA4	targetBased	344733	7043	non-small cell lung carcinoma	0.648573088621513	308
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	non-small cell lung carcinoma	0.709956252910777	4899
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	non-small cell lung carcinoma	0.709956252910777	4899
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	non-small cell lung carcinoma	0.709956252910777	4899
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	non-small cell lung carcinoma	0.709956252910777	4899
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	non-small cell lung carcinoma	0.709956252910777	4899
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	targetBased	356517	1139	non-small cell lung carcinoma	0.510746001221223	4077
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	non-small cell lung carcinoma	0.560157288727676	289
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	targetBased	276265	806	thyroid carcinoma	0.556084553629844	50
HTS of Smad transcription factor inhibitors	SMAD3	targetBased	88033	251	thyroid carcinoma	0.5522484605199	10
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	targetBased	193542	587	non-small cell lung carcinoma	0.600629550249717	203
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	non-small cell lung carcinoma	0.673534018217188	1970
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	brain neoplasm	0.516390636682191	6
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	brain neoplasm	0.516390636682191	6
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	brain neoplasm	0.646414536804601	648
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	brain neoplasm	0.646414536804601	648
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	brain neoplasm	0.646414536804601	648
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	brain neoplasm	0.646414536804601	648
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	brain neoplasm	0.646414536804601	648
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	targetBased	193542	587	brain neoplasm	0.52338689289213	78
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	pathwayBased	376029	3978	ovarian neoplasm	0.906277040676126	7663
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	ovarian neoplasm	0.800787973060319	1661
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	ovarian neoplasm	0.800787973060319	1661
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	ovarian neoplasm	0.800787973060319	1661
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	ovarian neoplasm	0.800787973060319	1661
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	ovarian neoplasm	0.800787973060319	1661
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	targetBased	356517	1139	ovarian neoplasm	0.518401315696728	245
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	targetBased	193542	587	ovarian neoplasm	0.73592106151764	111
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	ovarian neoplasm	0.578223516620776	256
Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	targetBased	329153	670	thyroid neoplasm	0.667632909500217	246
Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	targetBased	329153	670	thyroid neoplasm	0.667632909500217	246
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor	TSHR	targetBased	72026	352	thyroid neoplasm	0.667632909500217	246
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293	TSHR	targetBased	72026	1794	thyroid neoplasm	0.667632909500217	246
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	targetBased	194628	267	thyroid neoplasm	0.717923499573761	177
Nrf2 qHTS screen for inhibitors	nrf2Inhibitors	targetBased	360873	7438	uterine neoplasm	0.506284165020475	31
qHTS of Nrf2 Activators	Nrf2 activators	pathwayBased	403871	1243	uterine neoplasm	0.506284165020475	31
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	uterine neoplasm	0.60477961198684	1095
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	uterine neoplasm	0.60477961198684	1095
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	uterine neoplasm	0.60477961198684	1095
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	uterine neoplasm	0.60477961198684	1095
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	uterine neoplasm	0.60477961198684	1095
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	targetBased	193542	587	uterine neoplasm	0.580345234831025	177
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	pathwayBased	43989	342	uterine neoplasm	0.531396657480323	110
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	targetBased	334825	423	colorectal neoplasm	0.554868394038899	47
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	targetBased	337446	1356	colorectal neoplasm	0.554868394038899	47
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	targetBased	359207	1432	colorectal neoplasm	0.611627732068766	81
Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-gamma1).	PLCG1	targetBased	369953	3123	angiosarcoma	0.524654275968588	7
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	angiosarcoma	0.542272992084	75
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	angiosarcoma	0.542272992084	75
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	angiosarcoma	0.542272992084	75
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	angiosarcoma	0.542272992084	75
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	angiosarcoma	0.542272992084	75
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	pathwayBased	376029	3978	pancreatic neoplasm	0.589482433026752	212
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	targetBased	334825	423	pancreatic neoplasm	0.536472991523101	54
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	targetBased	337446	1356	pancreatic neoplasm	0.536472991523101	54
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	colorectal neoplasm	0.625072089258988	1870
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	colorectal neoplasm	0.625072089258988	1870
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	colorectal neoplasm	0.625072089258988	1870
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	colorectal neoplasm	0.625072089258988	1870
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	colorectal neoplasm	0.625072089258988	1870
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	targetBased	356517	1139	colorectal neoplasm	0.50059601177339	285
qHTS for Inhibitors of WRN Helicase	WRN	targetBased	364011	1678	colorectal neoplasm	0.513929896480345	19
HTS of Smad transcription factor inhibitors	SMAD3	targetBased	88033	251	colorectal neoplasm	0.544854494739693	43
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	targetBased	193542	587	colorectal neoplasm	0.614843970379271	382
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	stomach neoplasm	0.50387992859265	589
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	stomach neoplasm	0.50387992859265	589
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	stomach neoplasm	0.50387992859265	589
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	stomach neoplasm	0.50387992859265	589
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	stomach neoplasm	0.50387992859265	589
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	targetBased	193542	587	stomach neoplasm	0.500764838812246	68
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	stomach neoplasm	0.609719050629167	231
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	pancreatic neoplasm	0.808830166678429	1045
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	pancreatic neoplasm	0.808830166678429	1045
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	pancreatic neoplasm	0.808830166678429	1045
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	pancreatic neoplasm	0.808830166678429	1045
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	pancreatic neoplasm	0.808830166678429	1045
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	pancreatic neoplasm	0.664254622474054	127
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	pathwayBased	43989	342	colorectal neoplasm	0.502617440457158	133
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	kidney neoplasm	0.51632178998452	831
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	kidney neoplasm	0.51632178998452	831
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	kidney neoplasm	0.51632178998452	831
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	kidney neoplasm	0.51632178998452	831
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	kidney neoplasm	0.51632178998452	831
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	pathwayBased	43989	342	kidney neoplasm	0.550908270499343	1037
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	basal cell carcinoma	0.693049628473067	401
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	basal cell carcinoma	0.693049628473067	401
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	basal cell carcinoma	0.693049628473067	401
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	basal cell carcinoma	0.693049628473067	401
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	basal cell carcinoma	0.693049628473067	401
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	colonic neoplasm	0.521265092035978	689
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	colonic neoplasm	0.521265092035978	689
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	colonic neoplasm	0.521265092035978	689
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	colonic neoplasm	0.521265092035978	689
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	colonic neoplasm	0.521265092035978	689
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	colonic neoplasm	0.59125709347292	27
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	carcinoid tumor	0.53134326398704	73
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	carcinoid tumor	0.53134326398704	73
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	carcinoid tumor	0.53134326398704	73
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	carcinoid tumor	0.53134326398704	73
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	carcinoid tumor	0.53134326398704	73
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	targetBased	359207	1432	lymphoid leukemia	0.655837105084316	996
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	lymphoid leukemia	0.592682461616264	926
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	lymphoid leukemia	0.592682461616264	926
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	lymphoid leukemia	0.592682461616264	926
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	lymphoid leukemia	0.592682461616264	926
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	lymphoid leukemia	0.592682461616264	926
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	lymphoid leukemia	0.584126459536702	130
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	targetBased	217959	2390	myeloproliferative disorder	0.861829240204984	5324
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	upper aerodigestive tract neoplasm	0.578977454387374	45
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	nasopharyngeal neoplasm	0.699511170028026	49
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	nasopharyngeal neoplasm	0.699511170028026	49
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	nasopharyngeal neoplasm	0.699511170028026	49
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	nasopharyngeal neoplasm	0.699511170028026	49
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	nasopharyngeal neoplasm	0.699511170028026	49
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	targetBased	194628	267	nasopharyngeal neoplasm	0.501942833355626	6
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	targetBased	359207	1432	myeloproliferative disorder	0.6008959180227	3170
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	pathwayBased	376029	3978	lymph node metastatic carcinoma	0.54643680192594	81
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	lymph node metastatic carcinoma	0.537572300872626	29
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	glioma	0.518623288479843	2036
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	glioma	0.518623288479843	2036
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	glioma	0.518623288479843	2036
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	glioma	0.518623288479843	2036
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	glioma	0.518623288479843	2036
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	cholangiocarcinoma	0.598602455799827	436
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	cholangiocarcinoma	0.598602455799827	436
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	cholangiocarcinoma	0.598602455799827	436
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	cholangiocarcinoma	0.598602455799827	436
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	cholangiocarcinoma	0.598602455799827	436
HTS for BAP1 Enzyme inhibitors	BAP1_inhibitors	targetBased	71016	346	cholangiocarcinoma	0.512777658836874	32
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	esophageal squamous cell carcinoma	0.64655628137229	1225
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	esophageal squamous cell carcinoma	0.64655628137229	1225
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	esophageal squamous cell carcinoma	0.64655628137229	1225
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	esophageal squamous cell carcinoma	0.64655628137229	1225
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	esophageal squamous cell carcinoma	0.64655628137229	1225
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	esophageal squamous cell carcinoma	0.581722333143848	150
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	head and neck neoplasia	0.50151206457427	2001
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	head and neck neoplasia	0.50151206457427	2001
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	head and neck neoplasia	0.50151206457427	2001
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	head and neck neoplasia	0.50151206457427	2001
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	head and neck neoplasia	0.50151206457427	2001
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	head and neck neoplasia	0.554202837992371	247
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2_inhibitors	targetBased	57013	201	non-Hodgkins lymphoma	0.638504676439922	510
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	non-Hodgkins lymphoma	0.695708969907574	1850
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	non-Hodgkins lymphoma	0.695708969907574	1850
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	non-Hodgkins lymphoma	0.695708969907574	1850
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	non-Hodgkins lymphoma	0.695708969907574	1850
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	non-Hodgkins lymphoma	0.695708969907574	1850
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	pathwayBased	194666	1772	non-Hodgkins lymphoma	0.558721101467953	569
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	pathwayBased	194666	1722	non-Hodgkins lymphoma	0.558721101467953	569
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	non-Hodgkins lymphoma	0.643640984649825	451
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	head and neck malignant neoplasia	0.541944538639202	1771
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	head and neck malignant neoplasia	0.541944538639202	1771
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	head and neck malignant neoplasia	0.541944538639202	1771
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	head and neck malignant neoplasia	0.541944538639202	1771
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	head and neck malignant neoplasia	0.541944538639202	1771
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	head and neck malignant neoplasia	0.61852796016747	404
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	targetBased	86095	1442	male breast carcinoma	0.657373889939552	47
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	targetBased	86095	1151	male breast carcinoma	0.657373889939552	47
Nrf2 qHTS screen for inhibitors	nrf2Inhibitors	targetBased	360873	7438	bladder transitional cell carcinoma	0.510720357404753	27
qHTS of Nrf2 Activators	Nrf2 activators	pathwayBased	403871	1243	bladder transitional cell carcinoma	0.510720357404753	27
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	bladder transitional cell carcinoma	0.588845903637662	602
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	bladder transitional cell carcinoma	0.588845903637662	602
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	bladder transitional cell carcinoma	0.588845903637662	602
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	bladder transitional cell carcinoma	0.588845903637662	602
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	bladder transitional cell carcinoma	0.588845903637662	602
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	targetBased	193542	587	bladder transitional cell carcinoma	0.530771379279681	47
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	targetBased	194628	267	bladder transitional cell carcinoma	0.545118569063374	43
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	male reproductive organ cancer	0.518186328667181	44
Dicer-mediated maturation of pre-microRNA	Dicer_inhibitors	targetBased	46715	2829	pulmonary blastoma	0.540460032301018	138
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	urothelial carcinoma	0.51408234512013	433
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	urothelial carcinoma	0.51408234512013	433
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	urothelial carcinoma	0.51408234512013	433
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	urothelial carcinoma	0.51408234512013	433
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	urothelial carcinoma	0.51408234512013	433
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	digestive system neoplasm	0.599548825894144	391
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	targetBased	86095	1442	Hepatobiliary Neoplasm	0.510429822432812	274
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	targetBased	86095	1151	Hepatobiliary Neoplasm	0.510429822432812	274
Nrf2 qHTS screen for inhibitors	nrf2Inhibitors	targetBased	360873	7438	Hepatobiliary Neoplasm	0.535619794263082	174
qHTS of Nrf2 Activators	Nrf2 activators	pathwayBased	403871	1243	Hepatobiliary Neoplasm	0.535619794263082	174
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	Hepatobiliary Neoplasm	0.510567791113922	2837
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	Hepatobiliary Neoplasm	0.510567791113922	2837
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	Hepatobiliary Neoplasm	0.510567791113922	2837
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	Hepatobiliary Neoplasm	0.510567791113922	2837
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	Hepatobiliary Neoplasm	0.510567791113922	2837
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	targetBased	193542	587	Hepatobiliary Neoplasm	0.575005198667495	744
Dicer-mediated maturation of pre-microRNA	Dicer_inhibitors	targetBased	46715	2829	Pleuropulmonary blastoma	0.780118945779228	395
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	skin carcinoma	0.51020778667764	424
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	skin carcinoma	0.51020778667764	424
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	skin carcinoma	0.51020778667764	424
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	skin carcinoma	0.51020778667764	424
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	skin carcinoma	0.51020778667764	424
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	targetBased	193542	587	Pilomatrixoma	0.8876009025445	134
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	susceptibility to breast cancer	0.718849250077404	32
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	pathwayBased	376029	3978	secondary malignant neoplasm	0.604165201566678	34
qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide	Menin-MLL_inhibitors	targetBased	263421	615	pancreatic neuroendocrine tumor	0.633611610827445	356
HTS for BAP1 Enzyme inhibitors	BAP1_inhibitors	targetBased	71016	346	Malignant Mesothelioma	0.54276713631072	132
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	Malignant Pancreatic Neoplasm	0.662742907080579	519
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	Malignant Pancreatic Neoplasm	0.662742907080579	519
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	Malignant Pancreatic Neoplasm	0.662742907080579	519
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	Malignant Pancreatic Neoplasm	0.662742907080579	519
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	Malignant Pancreatic Neoplasm	0.662742907080579	519
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	Malignant Pancreatic Neoplasm	0.510758820729503	70
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	Malignant Pancreatic Neoplasm	0.572204935185042	204
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	Malignant Urinary System Neoplasm	0.52220433972734	1683
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	Malignant Urinary System Neoplasm	0.52220433972734	1683
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	Malignant Urinary System Neoplasm	0.52220433972734	1683
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	Malignant Urinary System Neoplasm	0.52220433972734	1683
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	Malignant Urinary System Neoplasm	0.52220433972734	1683
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	targetBased	217959	2390	Myelodysplastic/Myeloproliferative Neoplasm	0.515763988754042	39
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	targetBased	193542	587	Benign Skin Appendage Neoplasm	0.746464058544635	29
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	targetBased	193542	587	Hepatoblastoma	0.643412414649967	21
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	targetBased	86095	1442	HER2 Positive Breast Carcinoma	0.501942833355626	6
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	targetBased	86095	1151	HER2 Positive Breast Carcinoma	0.501942833355626	6
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	targetBased	359207	1432	Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive	0.667521194648004	21
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay	MAPK1	pathwayBased	70898	707	cervical squamous cell carcinoma	0.569304558236886	12
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF	MAPK1	pathwayBased	131324	544	cervical squamous cell carcinoma	0.569304558236886	12
Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity	SMARCA4	targetBased	344733	7043	Ovarian Small Cell Carcinoma	0.514054706433331	164
uHTS identification of HIF-2a Inhibitors in a luminesence assay	HIF-2a_inhibitors	targetBased	363840	2624	Paraganglioma	0.543000850613236	125
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	cervical squamous cell carcinoma	0.5768924431085	118
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	cervical squamous cell carcinoma	0.5768924431085	118
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	cervical squamous cell carcinoma	0.5768924431085	118
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	cervical squamous cell carcinoma	0.5768924431085	118
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	cervical squamous cell carcinoma	0.5768924431085	118
qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide	Menin-MLL_inhibitors	targetBased	263421	615	lung carcinoid tumor	0.67824858781795	26
Dicer-mediated maturation of pre-microRNA	Dicer_inhibitors	targetBased	46715	2829	Pineoblastoma	0.633859219992769	56
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	Choroid Plexus Papilloma	0.756303928580139	80
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	Choroid Plexus Papilloma	0.756303928580139	80
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	Choroid Plexus Papilloma	0.756303928580139	80
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	Choroid Plexus Papilloma	0.756303928580139	80
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	Choroid Plexus Papilloma	0.756303928580139	80
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	targetBased	334825	423	Pituitary Gland Adenoma	0.726268004475537	170
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	targetBased	337446	1356	Pituitary Gland Adenoma	0.726268004475537	170
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	Lung Sarcomatoid Carcinoma	0.543809040454276	22
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	Lung Sarcomatoid Carcinoma	0.543809040454276	22
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	Lung Sarcomatoid Carcinoma	0.543809040454276	22
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	Lung Sarcomatoid Carcinoma	0.543809040454276	22
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	Lung Sarcomatoid Carcinoma	0.543809040454276	22
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	Pleural Mesothelioma	0.642612657221498	75
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	Pleural Mesothelioma	0.642612657221498	75
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	Pleural Mesothelioma	0.642612657221498	75
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	Pleural Mesothelioma	0.642612657221498	75
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	Pleural Mesothelioma	0.642612657221498	75
HTS for BAP1 Enzyme inhibitors	BAP1_inhibitors	targetBased	71016	346	Pleural Mesothelioma	0.735350430677337	70
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	Digestive System Carcinoma	0.525636156396741	5759
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	Digestive System Carcinoma	0.525636156396741	5759
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	Digestive System Carcinoma	0.525636156396741	5759
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	Digestive System Carcinoma	0.525636156396741	5759
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	Digestive System Carcinoma	0.525636156396741	5759
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	Digestive System Carcinoma	0.503659990048741	223
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	targetBased	193542	587	Digestive System Carcinoma	0.512405747440022	957
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	targetBased	334825	423	pancreatic adenocarcinoma	0.678833343678363	36
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	targetBased	337446	1356	pancreatic adenocarcinoma	0.678833343678363	36
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	T-Cell Prolymphocytic Leukemia	0.623514123973518	57
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	pancreatic adenocarcinoma	0.787429982948732	847
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	pancreatic adenocarcinoma	0.787429982948732	847
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	pancreatic adenocarcinoma	0.787429982948732	847
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	pancreatic adenocarcinoma	0.787429982948732	847
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	pancreatic adenocarcinoma	0.787429982948732	847
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	targetBased	86095	1442	Endometrial Polyp	0.516802768100669	42
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	targetBased	86095	1151	Endometrial Polyp	0.516802768100669	42
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	pancreatic adenocarcinoma	0.606244963636864	149
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	Uterine Carcinosarcoma	0.671124202650939	228
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	Uterine Carcinosarcoma	0.671124202650939	228
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	Uterine Carcinosarcoma	0.671124202650939	228
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	Uterine Carcinosarcoma	0.671124202650939	228
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	Uterine Carcinosarcoma	0.671124202650939	228
HTS for BAP1 Enzyme inhibitors	BAP1_inhibitors	targetBased	71016	346	Uveal Melanoma	0.842672768448216	66
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	targetBased	359207	1432	marginal zone B-cell lymphoma	0.510788412662706	8
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	targetBased	339297	1446	hemangioma	0.641219378530656	62
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	pathwayBased	376029	3978	Genital neoplasm, female	0.756154198723462	7331
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	adrenal cortex carcinoma	0.772501421851151	549
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	adrenal cortex carcinoma	0.772501421851151	549
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	adrenal cortex carcinoma	0.772501421851151	549
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	adrenal cortex carcinoma	0.772501421851151	549
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	adrenal cortex carcinoma	0.772501421851151	549
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	targetBased	193542	587	adrenal cortex carcinoma	0.653106561534341	90
qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide	Menin-MLL_inhibitors	targetBased	263421	615	parathyroid adenoma	0.740465619640904	206
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	peritoneal neoplasm	0.557952605286964	96
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	targetBased	359207	1432	metastatic colorectal cancer	0.589434707125137	59
qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide	Menin-MLL_inhibitors	targetBased	263421	615	Angiofibroma	0.702187728399871	38
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	targetBased	359244	2975	chronic myelomonocytic leukemia	0.641149353645763	58
Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity	SMARCA4	targetBased	344733	7043	soft tissue sarcoma	0.500101901111415	2368
uHTS identification of small molecule inhibitors of Artemis endonuclease activity via a fluorescence intensity assay	artemis_inhibitors	targetBased	30104	235	histiocytic medullary reticulosis	0.616539346649504	312
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	pathwayBased	376029	3978	endometrial carcinoma	0.617724297967159	47
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	endometrial carcinoma	0.62230136368295	16
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	targetBased	143816	859	Mantle cell lymphoma	0.598331794844814	50
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	Mantle cell lymphoma	0.616608879193016	210
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	Mantle cell lymphoma	0.569305702678426	72
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	differentiated thyroid carcinoma	0.544852674219891	180
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	differentiated thyroid carcinoma	0.544852674219891	180
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	differentiated thyroid carcinoma	0.544852674219891	180
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	differentiated thyroid carcinoma	0.544852674219891	180
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	differentiated thyroid carcinoma	0.544852674219891	180
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	targetBased	276265	806	differentiated thyroid carcinoma	0.615477369838719	35
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	targetBased	194628	267	differentiated thyroid carcinoma	0.606300003374867	58
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	cutaneous squamous cell carcinoma	0.535642478113645	93
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	cutaneous squamous cell carcinoma	0.535642478113645	93
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	cutaneous squamous cell carcinoma	0.535642478113645	93
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	cutaneous squamous cell carcinoma	0.535642478113645	93
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	cutaneous squamous cell carcinoma	0.535642478113645	93
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	B-cell non-Hodgkins lymphoma	0.5234572186721	233
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	colon adenocarcinoma	0.563271617866096	225
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	colon adenocarcinoma	0.563271617866096	225
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	colon adenocarcinoma	0.563271617866096	225
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	colon adenocarcinoma	0.563271617866096	225
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	colon adenocarcinoma	0.563271617866096	225
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	335	colon carcinoma	0.592081065759334	57
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	782	colon carcinoma	0.592081065759334	57
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	390	colon carcinoma	0.592081065759334	57
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	811	colon carcinoma	0.592081065759334	57
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	670	colon carcinoma	0.592081065759334	57
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	519	colon carcinoma	0.592081065759334	57
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	colon carcinoma	0.563185208148079	25
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	targetBased	193542	587	colon carcinoma	0.588130234119545	137
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	gallbladder carcinoma	0.573784445368201	151
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	gallbladder carcinoma	0.573784445368201	151
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	gallbladder carcinoma	0.573784445368201	151
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	gallbladder carcinoma	0.573784445368201	151
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	gallbladder carcinoma	0.573784445368201	151
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	colon carcinoma	0.661335987264173	950
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	colon carcinoma	0.661335987264173	950
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	colon carcinoma	0.661335987264173	950
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	colon carcinoma	0.661335987264173	950
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	colon carcinoma	0.661335987264173	950
HTS for BAP1 Enzyme inhibitors	BAP1_inhibitors	targetBased	71016	346	Uveal melanoma	0.542772169908436	179
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	pathwayBased	376029	3978	gastric cancer	0.644706663355619	76
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	gastric cancer	0.72652111587925	459
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	gastric cancer	0.72652111587925	459
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	gastric cancer	0.72652111587925	459
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	gastric cancer	0.72652111587925	459
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	gastric cancer	0.72652111587925	459
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	gastric cancer	0.696672156439903	159
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	gastric cancer	0.583218527587673	405
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	brain cancer	0.537444841116938	459
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	brain cancer	0.537444841116938	459
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	brain cancer	0.537444841116938	459
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	brain cancer	0.537444841116938	459
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	brain cancer	0.537444841116938	459
Nrf2 qHTS screen for inhibitors	nrf2Inhibitors	targetBased	360873	7438	urinary bladder cancer	0.532337192362235	30
qHTS of Nrf2 Activators	Nrf2 activators	pathwayBased	403871	1243	urinary bladder cancer	0.532337192362235	30
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	urinary bladder cancer	0.761976143434719	875
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	urinary bladder cancer	0.761976143434719	875
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	urinary bladder cancer	0.761976143434719	875
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	urinary bladder cancer	0.761976143434719	875
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	urinary bladder cancer	0.761976143434719	875
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	urinary bladder cancer	0.634051822221657	72
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	targetBased	194628	267	urinary bladder cancer	0.756664701286372	130
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	pathwayBased	376029	3978	ovarian epithelial tumor	0.665791319751206	7078
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	ovarian epithelial tumor	0.69364717737818	786
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	ovarian epithelial tumor	0.69364717737818	786
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	ovarian epithelial tumor	0.69364717737818	786
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	ovarian epithelial tumor	0.69364717737818	786
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	ovarian epithelial tumor	0.69364717737818	786
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	vaginal cancer	0.525105070833845	10
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	vaginal cancer	0.525105070833845	10
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	vaginal cancer	0.525105070833845	10
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	vaginal cancer	0.525105070833845	10
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	vaginal cancer	0.525105070833845	10
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	targetBased	193542	587	epidermal appendage tumor	0.503317945774591	53
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	digestive system cancer	0.715610156304212	337
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	hematopoietic and lymphoid system neoplasm	0.511943760414391	550
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	head and neck carcinoma	0.511917474474916	1579
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	head and neck carcinoma	0.511917474474916	1579
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	head and neck carcinoma	0.511917474474916	1579
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	head and neck carcinoma	0.511917474474916	1579
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	head and neck carcinoma	0.511917474474916	1579
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	skin squamous cell carcinoma	0.608411208348797	413
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	skin squamous cell carcinoma	0.608411208348797	413
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	skin squamous cell carcinoma	0.608411208348797	413
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	skin squamous cell carcinoma	0.608411208348797	413
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	skin squamous cell carcinoma	0.608411208348797	413
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	targetBased	194628	267	skin squamous cell carcinoma	0.556633806525779	44
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	pathwayBased	376029	3978	peritoneum cancer	0.513391963949566	148
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	targetBased	276265	806	thyroid cancer	0.588445160784701	43
Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	targetBased	329153	670	thyroid cancer	0.603822893407619	156
Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	targetBased	329153	670	thyroid cancer	0.603822893407619	156
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor	TSHR	targetBased	72026	352	thyroid cancer	0.603822893407619	156
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293	TSHR	targetBased	72026	1794	thyroid cancer	0.603822893407619	156
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	cervical cancer	0.58247055398953	168
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	bone osteosarcoma	0.677273520190282	56
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	bone osteosarcoma	0.677273520190282	56
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	bone osteosarcoma	0.677273520190282	56
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	bone osteosarcoma	0.677273520190282	56
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	bone osteosarcoma	0.677273520190282	56
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	targetBased	86095	1442	breast carcinoma in situ	0.600945355982923	284
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	targetBased	86095	1151	breast carcinoma in situ	0.600945355982923	284
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	targetBased	86095	1114	breast carcinoma in situ	0.51521839195996	16
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	pathwayBased	376029	3978	bile duct adenocarcinoma	0.583775539396127	20
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	bile duct adenocarcinoma	0.50193157436328	15
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	adult acute lymphoblastic leukemia	0.6264758721618	42
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	pathwayBased	376029	3978	hereditary breast ovarian cancer syndrome	0.738790451491213	11288
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	hereditary breast ovarian cancer syndrome	0.577008661057121	104
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	hereditary breast ovarian cancer syndrome	0.577008661057121	104
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	hereditary breast ovarian cancer syndrome	0.577008661057121	104
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	hereditary breast ovarian cancer syndrome	0.577008661057121	104
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	hereditary breast ovarian cancer syndrome	0.577008661057121	104
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	hereditary breast ovarian cancer syndrome	0.592435458669846	338
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	pancreatic ductal adenocarcinoma	0.543444771738886	68
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	targetBased	359207	1432	myeloid leukemia	0.715357066963333	2551
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	targetBased	359244	2975	myeloid leukemia	0.537254273842718	378
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	pathwayBased	376029	3978	urinary bladder carcinoma	0.663159024758506	62
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	urinary bladder carcinoma	0.715943490770942	1968
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	urinary bladder carcinoma	0.715943490770942	1968
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	urinary bladder carcinoma	0.715943490770942	1968
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	urinary bladder carcinoma	0.715943490770942	1968
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	urinary bladder carcinoma	0.715943490770942	1968
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	urinary bladder carcinoma	0.732157805652173	127
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	targetBased	193542	587	urinary bladder carcinoma	0.579693725876986	67
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	targetBased	194628	267	urinary bladder carcinoma	0.733331528757895	307
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	pathwayBased	376029	3978	cancer	0.889745401546417	20752
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	gallbladder cancer	0.5934612972816	77
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	gallbladder cancer	0.5934612972816	77
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	gallbladder cancer	0.5934612972816	77
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	gallbladder cancer	0.5934612972816	77
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	gallbladder cancer	0.5934612972816	77
Small Molecule Inhibitors of FGF22-Mediated Excitatory Synaptogenesis & Epilepsy Measured in Biochemical System Using RT-PCR - 7012-01_Inhibitor_SinglePoint_HTS_Activity	FGF22_inhibitors	targetBased	339650	5128	cancer	0.668938724864321	38
HTS for Tumor Hsp90 Inhibitors	HSP90 known inhibitor displacement	targetBased	63696	220	cancer	0.742522421363885	1330
Luminescence-based primary biochemical high throughput screening assay to identify inhibitors of the Heat Shock Protein 90 (HSP90)	HSP90AA1	targetBased	290726	2649	cancer	0.742522421363885	1330
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	targetBased	290355	265	cancer	0.612317425813566	73
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	pathwayBased	376029	3978	colorectal cancer	0.557138707214907	161
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	targetBased	359207	1432	colorectal cancer	0.616184208009642	82
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	targetBased	86095	1442	cancer	0.669757231333485	16724
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	targetBased	86095	1151	cancer	0.669757231333485	16724
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	targetBased	217959	2390	cancer	0.753722443923473	6564
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	targetBased	359207	1432	cancer	0.54326808569933	4699
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay	MAPK1	pathwayBased	70898	707	cancer	0.762437302926748	1581
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF	MAPK1	pathwayBased	131324	544	cancer	0.762437302926748	1581
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	targetBased	143816	859	cancer	0.728959503512403	614
qHTS Assay for Inhibitors of the CtBP/E1A Interaction	RBBP8	targetBased	335214	1652	cancer	0.653448141858887	163
qHTS for Inhibitors of TGF-b	TGFB1	pathwayBased	403345	4970	cancer	0.624251650790347	22455
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	colorectal cancer	0.517736107458662	9
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	colorectal cancer	0.517736107458662	9
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2_inhibitors	targetBased	57013	201	cancer	0.596441371396059	6110
qHTS Assay for Inhibitors of GCN5L2	KAT2A	targetBased	381571	792	cancer	0.679538557997074	140
Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex	PRKAR1A	targetBased	343468	285	cancer	0.677194877664189	166
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	cancer	0.705430116689074	449
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	cancer	0.705430116689074	449
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	colorectal cancer	0.824947173642699	1104
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	colorectal cancer	0.824947173642699	1104
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	colorectal cancer	0.824947173642699	1104
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	colorectal cancer	0.824947173642699	1104
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	colorectal cancer	0.824947173642699	1104
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	colorectal cancer	0.692377036344037	58
qHTS for Inhibitors of WRN Helicase	WRN	targetBased	364011	1678	colorectal cancer	0.507044449991793	11
HTS of Smad transcription factor inhibitors	SMAD3	targetBased	88033	251	colorectal cancer	0.591112604809797	25
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	targetBased	193542	587	colorectal cancer	0.682157692026859	193
Primary cell-based high throughput screening assay to measure STAT1 activation	STAT1 activation	pathwayBased	195980	5134	cancer	0.63814917384931	1823
Primary cell-based high throughput screening assay to measure STAT1 inhibition	STAT1	targetBased	195980	695	cancer	0.63814917384931	1823
qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM)	BLM_inhibitors	targetBased	347933	673	colorectal cancer	0.546180532377725	11
Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-gamma1).	PLCG1	targetBased	369953	3123	cancer	0.730312854683163	391
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	targetBased	359244	2975	cancer	0.728900443873601	3505
E3 Ligase HTS_1536	MDM2	targetBased	207811	220	cancer	0.572600603058696	5421
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac activated mutant	RAC1	targetBased	194629	219	cancer	0.577800245386886	206
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac wildtype	RAC1	targetBased	194628	521	cancer	0.577800245386886	206
Assay for Inhibitors of the beta-Arrestin-Adaptor Protein 2 Interaction That Mediate GPCR Degradation and Recycling	ARRB1_inhibitors	targetBased	338373	1061	cancer	0.69134586295159	158
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	targetBased	305610	3878	Beckwith-Wiedemann syndrome	0.610955952556363	174
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	targetBased	305610	1082	Beckwith-Wiedemann syndrome	0.610955952556363	174
qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide	Menin-MLL_inhibitors	targetBased	263421	615	multiple endocrine neoplasia type 1	0.955651497731723	4107
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	targetBased	86095	1114	cancer	0.607180358680722	1859
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	cancer	0.798462583624305	70480
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	cancer	0.798462583624305	70480
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	cancer	0.798462583624305	70480
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	cancer	0.798462583624305	70480
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	cancer	0.798462583624305	70480
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	targetBased	356517	1139	cancer	0.835992187469882	39501
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	targetBased	108286	1415	cancer	0.504017619130342	164
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	targetBased	359518	300	cancer	0.573653134243772	251
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	targetBased	335652	1779	cancer	0.573653134243772	251
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	targetBased	362274	1056	cancer	0.573653134243772	251
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	targetBased	336308	6862	cancer	0.573653134243772	251
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	targetBased	357537	806	cancer	0.573653134243772	251
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	targetBased	339887	1178	cancer	0.573653134243772	251
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	cancer	0.887742187650375	6406
Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.	BCL2L11_inhibitors	targetBased	325630	216	cancer	0.663322592053893	1001
HTS for BAP1 Enzyme inhibitors	BAP1_inhibitors	targetBased	71016	346	cancer	0.503838946288405	618
Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity	SMARCA4	targetBased	344733	7043	esophageal cancer	0.572918676553839	22
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	esophageal cancer	0.755733859976898	808
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	esophageal cancer	0.755733859976898	808
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	esophageal cancer	0.755733859976898	808
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	esophageal cancer	0.755733859976898	808
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	esophageal cancer	0.755733859976898	808
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	esophageal cancer	0.500369861549014	257
HTS of Smad transcription factor inhibitors	SMAD3	targetBased	88033	251	cancer	0.660773367238811	1157
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	targetBased	193542	587	cancer	0.729137686870591	4215
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	pathwayBased	194666	1772	cancer	0.74895001267032	16259
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	pathwayBased	194666	1722	cancer	0.74895001267032	16259
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	targetBased	339297	1446	cancer	0.521979003500729	323
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	targetBased	305610	3794	cancer	0.565605347025387	92
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	targetBased	339674	2841	cancer	0.56085201851383	53
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	targetBased	369953	760	cancer	0.695643178729002	130
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	targetBased	369953	498	cancer	0.695643178729002	130
Primary cell-based high-throughput screening assay to measure PERK inhibition	PERK_inhibitors	targetBased	217959	370	cancer	0.590706185930871	934
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	targetBased	194628	267	cancer	0.80515992647272	2411
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	cancer	0.66498110324478	4383
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	targetBased	316642	617	cancer	0.532685560698662	562
qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM)	BLM_inhibitors	targetBased	347933	673	cancer	0.70224437864131	665
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	pathwayBased	43989	342	cancer	0.501389938673998	20821
Dicer-mediated maturation of pre-microRNA	Dicer_inhibitors	targetBased	46715	2829	goiter, multinodular 1, with or without Sertoli-Leydig cell tumors	0.786101469175161	83
qHTS for Inhibitors of WRN Helicase	WRN	targetBased	364011	1678	cancer	0.713286180158294	565
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	pathwayBased	376029	3978	breast cancer	0.864119807394064	12264
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	targetBased	86095	1442	breast cancer	0.837897580570166	12265
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	targetBased	86095	1151	breast cancer	0.837897580570166	12265
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	targetBased	359207	1432	breast cancer	0.528340798710332	266
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	breast cancer	0.570632065715757	30
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	breast cancer	0.570632065715757	30
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	targetBased	194628	267	nevus, epidermal	0.765990926960034	47
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	targetBased	194628	267	linear nevus sebaceous syndrome	0.803862671575397	54
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	targetBased	86095	1114	breast cancer	0.690361420729005	871
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	breast cancer	0.793469661384171	4260
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	breast cancer	0.793469661384171	4260
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	breast cancer	0.793469661384171	4260
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	breast cancer	0.793469661384171	4260
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	breast cancer	0.793469661384171	4260
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	targetBased	356517	1139	breast cancer	0.612252208871859	2961
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	breast cancer	0.771774175297562	2611
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	adrenocortical carcinoma, hereditary	0.732277820907482	320
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	adrenocortical carcinoma, hereditary	0.732277820907482	320
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	adrenocortical carcinoma, hereditary	0.732277820907482	320
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	adrenocortical carcinoma, hereditary	0.732277820907482	320
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	adrenocortical carcinoma, hereditary	0.732277820907482	320
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	breast cancer	0.686684940581599	2847
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	pathwayBased	376029	3978	ovarian cancer	0.902464031304924	7268
Dicer-mediated maturation of pre-microRNA	Dicer_inhibitors	targetBased	46715	2829	ovarian cancer	0.501322871917439	40
uHTS identification of small molecule modulators of NR3A	GRIN3A	targetBased	339772	8480	breast cancer	0.520819643474188	6
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	ovarian cancer	0.783276111831291	1196
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	ovarian cancer	0.783276111831291	1196
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	ovarian cancer	0.783276111831291	1196
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	ovarian cancer	0.783276111831291	1196
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	ovarian cancer	0.783276111831291	1196
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	targetBased	356517	1139	ovarian cancer	0.509499952146859	147
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	ovarian cancer	0.533934187309719	334
qHTS for Inhibitors of WRN Helicase	WRN	targetBased	364011	1678	ovarian cancer	0.549119798919808	36
Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	targetBased	329153	670	ovarian cancer	0.510139151355727	22
Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	targetBased	329153	670	ovarian cancer	0.510139151355727	22
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor	TSHR	targetBased	72026	352	ovarian cancer	0.510139151355727	22
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293	TSHR	targetBased	72026	1794	ovarian cancer	0.510139151355727	22
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	targetBased	193542	587	ovarian cancer	0.732513052579539	72
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	ovarian cancer	0.596469532383122	482
qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM)	BLM_inhibitors	targetBased	347933	673	ovarian cancer	0.520714652864584	43
qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM)	BLM_inhibitors	targetBased	347933	673	Bloom syndrome	0.937191544742725	5934
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	lung cancer	0.528383497749928	27
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	lung cancer	0.528383497749928	27
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	lung cancer	0.536966635791938	1331
qHTS for Inhibitors of Polymerase Kappa	POLK	targetBased	395295	2034	prostate cancer	0.600041049899183	53
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	prostate cancer	0.56074255087829	294
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	prostate cancer	0.56074255087829	294
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	prostate cancer	0.56074255087829	294
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	prostate cancer	0.56074255087829	294
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	prostate cancer	0.56074255087829	294
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	prostate cancer	0.650787355768156	872
Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex	PRKAR1A	targetBased	343468	285	familial atrial myxoma	0.669881265397799	39
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	targetBased	215667	993	hereditary thrombocytopenia and hematologic cancer predisposition syndrome	0.796724875126738	3169
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	targetBased	218234	1620	hereditary thrombocytopenia and hematologic cancer predisposition syndrome	0.796724875126738	3169
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	targetBased	86095	1442	endometrial cancer	0.551806592823691	253
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	targetBased	86095	1151	endometrial cancer	0.551806592823691	253
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	targetBased	359207	1432	gastrointestinal stromal tumor	0.666559986194665	320
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	endometrial cancer	0.719716014087321	348
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	endometrial cancer	0.719716014087321	348
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	endometrial cancer	0.719716014087321	348
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	endometrial cancer	0.719716014087321	348
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	endometrial cancer	0.719716014087321	348
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	targetBased	356517	1139	endometrial cancer	0.582805616721057	119
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	endometrial cancer	0.539805519610671	45
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	targetBased	193542	587	endometrial cancer	0.674111345989311	123
HTS for BAP1 Enzyme inhibitors	BAP1_inhibitors	targetBased	71016	346	BAP1-related tumor predisposition syndrome	0.895619429083368	3174
qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide	Menin-MLL_inhibitors	targetBased	263421	615	familial isolated hyperparathyroidism	0.55473784931811	85
High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen	NFKB1	pathwayBased	193265	3100	common variable immunodeficiency	0.834779616196932	290
uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay	NFKB1	pathwayBased	359244	3094	common variable immunodeficiency	0.834779616196932	290
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	pathwayBased	376029	3978	familial pancreatic carcinoma	0.502665805472282	18
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	familial pancreatic carcinoma	0.690429985228812	80
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	familial pancreatic carcinoma	0.690429985228812	80
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	familial pancreatic carcinoma	0.690429985228812	80
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	familial pancreatic carcinoma	0.690429985228812	80
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	familial pancreatic carcinoma	0.690429985228812	80
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	familial pancreatic carcinoma	0.557390044105614	26
qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1)	RECQL	targetBased	234915	1245	hereditary neoplastic syndrome	0.555826756510399	103
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	pathwayBased	376029	3978	hereditary neoplastic syndrome	0.738658920587182	17319
Dicer-mediated maturation of pre-microRNA	Dicer_inhibitors	targetBased	46715	2829	hereditary neoplastic syndrome	0.694777963492794	4859
Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex	PRKAR1A	targetBased	343468	285	hereditary neoplastic syndrome	0.59216265599301	644
Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity	SMARCA4	targetBased	344733	7043	hereditary neoplastic syndrome	0.706743784625669	6520
qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide	Menin-MLL_inhibitors	targetBased	263421	615	hereditary neoplastic syndrome	0.733240953654702	3378
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	hereditary neoplastic syndrome	0.745817539826029	5525
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	hereditary neoplastic syndrome	0.745817539826029	5525
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	hereditary neoplastic syndrome	0.745817539826029	5525
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	hereditary neoplastic syndrome	0.745817539826029	5525
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	hereditary neoplastic syndrome	0.745817539826029	5525
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	hereditary neoplastic syndrome	0.657217545791875	14264
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	targetBased	215667	993	hereditary neoplastic syndrome	0.545499608537802	1596
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	targetBased	218234	1620	hereditary neoplastic syndrome	0.545499608537802	1596
HTS for BAP1 Enzyme inhibitors	BAP1_inhibitors	targetBased	71016	346	hereditary neoplastic syndrome	0.720820341742928	3689
MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity	MITF	targetBased	331360	2760	hereditary neoplastic syndrome	0.570307346678232	260
AlphaScreen-based biochemical high throughput primary assay to identify inhibitors of microphthalmia-associated transcription factor (MITF)	MITF inhibitors	targetBased	642362	5830	hereditary neoplastic syndrome	0.570307346678232	260
qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM)	BLM_inhibitors	targetBased	347933	673	hereditary neoplastic syndrome	0.635838473701773	3305
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	targetBased	356517	1139	Cowden disease	0.535270059891584	275
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	pathwayBased	376029	3978	hereditary breast carcinoma	0.89275999234869	1170
Identification of Molecular Probes that Activate MRP-1	ABCC1_activators	targetBased	138717	842	hereditary breast carcinoma	0.521402826406466	18
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	hereditary breast carcinoma	0.746971472284402	108
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	hereditary breast carcinoma	0.746971472284402	108
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	hereditary breast carcinoma	0.746971472284402	108
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	hereditary breast carcinoma	0.746971472284402	108
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	hereditary breast carcinoma	0.746971472284402	108
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	hereditary breast carcinoma	0.79096845653944	4641
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	targetBased	359207	1432	systemic mastocytosis	0.516815843873698	12
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	targetBased	356517	1139	meningioma	0.516735037687015	12
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	targetBased	194628	267	phakomatosis pigmentokeratotica	0.508862452109535	6
Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3	HDAC3	targetBased	318291	483	T-cell non-Hodgkin lymphoma	0.563737443355213	18
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	choroid plexus carcinoma	0.592216076816502	68
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	choroid plexus carcinoma	0.592216076816502	68
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	choroid plexus carcinoma	0.592216076816502	68
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	choroid plexus carcinoma	0.592216076816502	68
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	choroid plexus carcinoma	0.592216076816502	68
Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity	SMARCA4	targetBased	344733	7043	familial rhabdoid tumor	0.874158218818574	6884
qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide	Menin-MLL_inhibitors	targetBased	263421	615	multiple endocrine neoplasia	0.767584741814198	1559
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	targetBased	194628	267	epidermal nevus syndrome	0.519410926301161	6
Dicer-mediated maturation of pre-microRNA	Dicer_inhibitors	targetBased	46715	2829	global developmental delay - lung cysts - overgrowth - Wilms tumor syndrome	0.773844445367218	506
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	pathwayBased	376029	3978	carcinoma of liver and intrahepatic biliary tract	0.502012600305333	78
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	targetBased	334825	423	carcinoma of liver and intrahepatic biliary tract	0.51063753622872	34
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	targetBased	337446	1356	carcinoma of liver and intrahepatic biliary tract	0.51063753622872	34
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	Li-Fraumeni syndrome	0.961183981598178	6950
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	Li-Fraumeni syndrome	0.961183981598178	6950
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	Li-Fraumeni syndrome	0.961183981598178	6950
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	Li-Fraumeni syndrome	0.961183981598178	6950
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	Li-Fraumeni syndrome	0.961183981598178	6950
Nrf2 qHTS screen for inhibitors	nrf2Inhibitors	targetBased	360873	7438	carcinoma of liver and intrahepatic biliary tract	0.529180688127008	146
qHTS of Nrf2 Activators	Nrf2 activators	pathwayBased	403871	1243	carcinoma of liver and intrahepatic biliary tract	0.529180688127008	146
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	carcinoma of liver and intrahepatic biliary tract	0.508700009478479	2659
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	carcinoma of liver and intrahepatic biliary tract	0.508700009478479	2659
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	carcinoma of liver and intrahepatic biliary tract	0.508700009478479	2659
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	carcinoma of liver and intrahepatic biliary tract	0.508700009478479	2659
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	carcinoma of liver and intrahepatic biliary tract	0.508700009478479	2659
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	carcinoma of liver and intrahepatic biliary tract	0.510579263830081	59
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	targetBased	193542	587	carcinoma of liver and intrahepatic biliary tract	0.56918270779896	653
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	targetBased	359207	1432	follicular lymphoma	0.589403135644704	24
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2_inhibitors	targetBased	57013	201	follicular lymphoma	0.560395370472155	227
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	follicular lymphoma	0.625483391400951	95
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	adult T-cell leukemia/lymphoma	0.55928325716652	8
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	low grade glioma	0.647024924444588	163
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	low grade glioma	0.647024924444588	163
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	low grade glioma	0.647024924444588	163
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	low grade glioma	0.647024924444588	163
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	low grade glioma	0.647024924444588	163
Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex	PRKAR1A	targetBased	343468	285	malignant endocrine neoplasm	0.63675759302262	43
qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide	Menin-MLL_inhibitors	targetBased	263421	615	malignant endocrine neoplasm	0.607624213372651	402
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	malignant endocrine neoplasm	0.63110038811149	4107
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	malignant endocrine neoplasm	0.63110038811149	4107
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	malignant endocrine neoplasm	0.63110038811149	4107
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	malignant endocrine neoplasm	0.63110038811149	4107
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	malignant endocrine neoplasm	0.63110038811149	4107
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	lung neoplasm	0.517562541508203	954
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	lip and oral cavity carcinoma	0.661600167112357	634
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	lip and oral cavity carcinoma	0.661600167112357	634
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	lip and oral cavity carcinoma	0.661600167112357	634
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	lip and oral cavity carcinoma	0.661600167112357	634
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	lip and oral cavity carcinoma	0.661600167112357	634
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	targetBased	194628	267	lip and oral cavity carcinoma	0.626887753244379	60
HTS for BAP1 Enzyme inhibitors	BAP1_inhibitors	targetBased	71016	346	melanocytic neoplasm	0.504583292790778	93
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	targetBased	194628	267	melanocytic neoplasm	0.57720847430598	187
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	familial prostate carcinoma	0.516875235389713	6
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	uterine cervix neoplasm	0.544959939222638	510
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	uterine cervix neoplasm	0.544959939222638	510
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	uterine cervix neoplasm	0.544959939222638	510
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	uterine cervix neoplasm	0.544959939222638	510
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	uterine cervix neoplasm	0.544959939222638	510
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	targetBased	193542	587	endometrium neoplasm	0.516566251982747	98
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	targetBased	215667	993	hereditary thrombocytopenia and hematological cancer predisposition syndrome associated with RUNX1	0.882670337369514	2060
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	targetBased	218234	1620	hereditary thrombocytopenia and hematological cancer predisposition syndrome associated with RUNX1	0.882670337369514	2060
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	targetBased	194628	267	large congenital melanocytic nevus	0.654965888031878	32
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	targetBased	194628	267	oral cavity carcinoma	0.51917183544761	40
qHTS for Inhibitors of Polymerase Kappa	POLK	targetBased	395295	2034	Familial prostate cancer	0.596214509781827	32
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	pathwayBased	376029	3978	Hereditary breast cancer	0.836992105233513	7631
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	malignant glioma	0.667419094877046	1888
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	malignant glioma	0.667419094877046	1888
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	malignant glioma	0.667419094877046	1888
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	malignant glioma	0.667419094877046	1888
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	malignant glioma	0.667419094877046	1888
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	pathwayBased	376029	3978	Hereditary breast and ovarian cancer syndrome	0.905263436460505	20171
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	Hereditary breast and ovarian cancer syndrome	0.617356887059384	249
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	Hereditary breast and ovarian cancer syndrome	0.617356887059384	249
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	Hereditary breast and ovarian cancer syndrome	0.617356887059384	249
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	Hereditary breast and ovarian cancer syndrome	0.617356887059384	249
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	Hereditary breast and ovarian cancer syndrome	0.617356887059384	249
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	Hereditary breast and ovarian cancer syndrome	0.628101650010634	752
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	targetBased	194628	267	Linear nevus sebaceus syndrome	0.782821035564354	47
Primary Cell-based High Throughput Screening assay for activators of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	targetBased	64908	1225	Genetic 46,XY disorder of sex development	0.540259668835204	12
Primary Cell-based High Throughput Screening assay for inhibitors of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	targetBased	64908	359	Genetic 46,XY disorder of sex development	0.540259668835204	12
Dicer-mediated maturation of pre-microRNA	Dicer_inhibitors	targetBased	46715	2829	Global developmental delay-lung cysts-overgrowth-Wilms tumor syndrome	0.509035254749426	9

Some of these associations have also gone through clinical trials, as those in the graph below.

graph

Find clinical trials details in table. Use scroll bar or search funtion to select specific drugs, molecular targets or diseases.

table